Symbols

CORT

Corcept Therapeutics·NASDAQ

--(--)

CORT fundamentals

CORT Q4 2025 Earnings

Corcept Therapeutics (CORT) released its earnings on Feb 24, 2026: revenue was 202.13M (YoY +11.12%), missed estimates; EPS was 0.2 (YoY -23.08%), missed estimates.

Revenue / YoY

202.13M

+11.12%

EPS / YoY

0.2

-23.08%

Report date

Feb 24, 2026

CORT Earnings Call Summary for Q4,2025

Revenue Growth: 2025 revenue $761M (+13% YoY); 2026 guidance $900-1B.
Legal Battles: Federal Circuit ruled against generic Korlym; FDA denied relacorilant NDA.
Cushing's Business: 61% new prescriptions YoY; 37% tablet growth post pharmacy transition.
Oncology Success: ROSELLA trial showed 35% OS improvement in ovarian cancer.
Pipeline Momentum: DAZZLE ALS trial 84% mortality risk reduction; MONARCH MASH trial enrollment complete.

Earnings

EPS

Revenue

Revenue & Expenses

CORT has released its 2025 Q4 earnings report, with revenue of 202.13M, reflecting a YoY change of 11.12%, and net profit of 24.29M, showing a YoY change of -21.00%. The Sankey diagram below clearly presents CORT's revenue sources and cost distribution.

Key Indicators

Corcept Therapeutics (CORT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Corcept Therapeutics (CORT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Corcept Therapeutics (CORT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Corcept Therapeutics (CORT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown